Alpha-1 antitrypsin deficiency and primary liver cancers

Area of Science:

• Hepatology and Genetic Medicine
• Oncology
• Bioinformatics

Background:

• Primary liver cancers (PLCs) pose a growing global health challenge.
• Alpha 1-AntiTrypsin Deficiency (AATD) is an emerging risk factor for PLCs, particularly hepatocellular carcinoma (HCC).
• Individuals with AATD have a 20-50 fold increased risk of developing PLCs, yet the underlying mechanisms remain poorly understood.

Purpose of the Study:

• To review current knowledge on AATD-associated PLCs, focusing on genotype-specific impacts.
• To explore emerging hypotheses on the role of the AATD PiZZ genotype in hepatic carcinogenesis.
• To analyze UK Biobank data to confirm AATD PiZZ as an HCC risk factor.

Main Methods:

• Literature review of AATD and liver cancer associations.
• Exploration of molecular and genetic hypotheses for AATD-related hepatocarcinogenesis.
• Statistical analysis of the UK Biobank database.

Main Results:

• AATD, particularly the PiZZ genotype, is a significant risk factor for primary liver cancer.
• The UK Biobank analysis confirms the AATD PiZZ genotype's role in increasing HCC risk.
• Understanding genotype-specific risks is crucial for AATD-related liver disease management.

Conclusions:

• Alpha 1-AntiTrypsin Deficiency (AATD) is a critical genetic risk factor for primary liver cancers, especially HCC.
• The PiZZ genotype is strongly implicated in the development of AATD-associated HCC.
• Further research into AATD-related carcinogenesis is warranted to improve patient outcomes.